ArticleCell death discovery2025
Evidence of fructose metabolism in colorectal cancer.
Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell and spatial transcriptomics reveal lactate-active epithelial-immune cell crosstalk that reprograms the immune microenvironment in colorectal cancer.Translational oncology · 2026Article
- Metabolomics and proteomics analyses reveal the potiental mechanisms underlying colorectal cancer and chemotherapy targets.BMC cancer · 2026Article
- Protein lactylation: a metabolic signal driving cancer therapy resistance.Cell death discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) represents a significant global health burden, contributing significantly to cancer-related mortality. The underlying genetic and metabolic underpinnings of CRC remain incompletely understood. In this study, we conducted a comprehensive investigation into metabolic perturbations in 29 CRC patients utilizing targeted omics approaches, compared to public databases. Additionally, we examined serum and tissue samples from 12 patients, with and without preoperative glucose challenge, using targeted metabolomics to investigate glucose and fructose metabolism. Notably, elevated levels of serum D-Fructose and L-Lactic acid following glucose administration indicate augmented glycolytic activity and polyol pathway-mediated glucose conversion (to fructose). Despite variations in tumor responses, our results underscore the potential significance of fructose metabolism in CRC progression, shedding light on therapeutic avenues targeting the Warburg effect. This research lays a solid foundation for future translational research into metabolic interventions in CRC treatment and enhances our understanding of cancer-related metabolic reprogramming.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.